Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma

Oliver Yoa‐Pu Hu, Shiu‐Pei ‐P Chang, Chi‐Kong ‐K Law, Jer‐Min ‐M Jian, Kuang‐Yao ‐Y Chen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The pharmacokinetics and pharmacodynamics of mitoxantrone were studied in 15 patients with advanced nasopharyngeal carcinoma (NPC) after single intravenous rapid infusion (12 to 14 mg/m2). Mitoxantrone plasma concentrations and urinary excretion were measured specifically with the use of a high‐performance liquid chromatographic method with ultraviolet detection at 242 and 658 nm. The pharmacokinetic parameters are described adequately by a three‐compartment model with a terminal half‐life of 71.5 ± 40.1 hours and a volume of distribution of 5037 ± 2377 l0. The total plasma clearance was 743 ± 462 ml/minute, and the renal clearance was 18.8 ± 8.49 ml/minute. Within 72 hours, 1.8 ± 0.6% of the administration dose was excreted in urine as mitoxantrone parent compound. From the urinary excretion rate data, glomerular filtration and possible tubular reabsorption were the mechanisms involved in the urinary excretion of mitoxantrone. The values for unbound fraction (%) in plasma at time 0 and 5 minutes were 2.88 ± 0.91% and 3.25 ± 1.19%, with an average of 3.04 ± 1.01%. The degree of protein binding of mitoxantrone was not affected by concentration (P > 0.05) in Chinese patients with NPC. The response rate for mitoxantrone was poor in this study. Clinical studies have demonstrated that mitoxantrone was generally well tolerated. Only very low incidences of nausea, vomiting, and alopecia were observed. The mild and rapidly reversible dose‐limiting hematologic toxic effects have proven leukopenia. Although the toxicities reported here were tolerated for most patients, other combination regimens including mitoxantrone or other administration routes may be considered and need to be evaluated carefully. Cancer 1992; 69:847–853.

Original languageEnglish
Pages (from-to)847-853
Number of pages7
JournalCancer
Volume69
Issue number4
DOIs
Publication statusPublished - Jan 1 1992
Externally publishedYes

Fingerprint

Mitoxantrone
Pharmacokinetics
Therapeutics
Nasopharyngeal carcinoma
Poisons
Alopecia
Leukopenia
Glomerular Filtration Rate
Intravenous Infusions
Protein Binding
Nausea
Vomiting
Half-Life
Urine
Kidney
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. / Hu, Oliver Yoa‐Pu; Chang, Shiu‐Pei ‐P; Law, Chi‐Kong ‐K; Jian, Jer‐Min ‐M; Chen, Kuang‐Yao ‐Y.

In: Cancer, Vol. 69, No. 4, 01.01.1992, p. 847-853.

Research output: Contribution to journalArticle

Hu, Oliver Yoa‐Pu ; Chang, Shiu‐Pei ‐P ; Law, Chi‐Kong ‐K ; Jian, Jer‐Min ‐M ; Chen, Kuang‐Yao ‐Y. / Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. In: Cancer. 1992 ; Vol. 69, No. 4. pp. 847-853.
@article{d972b8f840dc4b3c919cc4ba3f94634a,
title = "Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma",
abstract = "The pharmacokinetics and pharmacodynamics of mitoxantrone were studied in 15 patients with advanced nasopharyngeal carcinoma (NPC) after single intravenous rapid infusion (12 to 14 mg/m2). Mitoxantrone plasma concentrations and urinary excretion were measured specifically with the use of a high‐performance liquid chromatographic method with ultraviolet detection at 242 and 658 nm. The pharmacokinetic parameters are described adequately by a three‐compartment model with a terminal half‐life of 71.5 ± 40.1 hours and a volume of distribution of 5037 ± 2377 l0. The total plasma clearance was 743 ± 462 ml/minute, and the renal clearance was 18.8 ± 8.49 ml/minute. Within 72 hours, 1.8 ± 0.6{\%} of the administration dose was excreted in urine as mitoxantrone parent compound. From the urinary excretion rate data, glomerular filtration and possible tubular reabsorption were the mechanisms involved in the urinary excretion of mitoxantrone. The values for unbound fraction ({\%}) in plasma at time 0 and 5 minutes were 2.88 ± 0.91{\%} and 3.25 ± 1.19{\%}, with an average of 3.04 ± 1.01{\%}. The degree of protein binding of mitoxantrone was not affected by concentration (P > 0.05) in Chinese patients with NPC. The response rate for mitoxantrone was poor in this study. Clinical studies have demonstrated that mitoxantrone was generally well tolerated. Only very low incidences of nausea, vomiting, and alopecia were observed. The mild and rapidly reversible dose‐limiting hematologic toxic effects have proven leukopenia. Although the toxicities reported here were tolerated for most patients, other combination regimens including mitoxantrone or other administration routes may be considered and need to be evaluated carefully. Cancer 1992; 69:847–853.",
author = "Hu, {Oliver Yoa‐Pu} and Chang, {Shiu‐Pei ‐P} and Law, {Chi‐Kong ‐K} and Jian, {Jer‐Min ‐M} and Chen, {Kuang‐Yao ‐Y}",
year = "1992",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19920215)69:4<847::AID-CNCR2820690402>3.0.CO;2-L",
language = "English",
volume = "69",
pages = "847--853",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma

AU - Hu, Oliver Yoa‐Pu

AU - Chang, Shiu‐Pei ‐P

AU - Law, Chi‐Kong ‐K

AU - Jian, Jer‐Min ‐M

AU - Chen, Kuang‐Yao ‐Y

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The pharmacokinetics and pharmacodynamics of mitoxantrone were studied in 15 patients with advanced nasopharyngeal carcinoma (NPC) after single intravenous rapid infusion (12 to 14 mg/m2). Mitoxantrone plasma concentrations and urinary excretion were measured specifically with the use of a high‐performance liquid chromatographic method with ultraviolet detection at 242 and 658 nm. The pharmacokinetic parameters are described adequately by a three‐compartment model with a terminal half‐life of 71.5 ± 40.1 hours and a volume of distribution of 5037 ± 2377 l0. The total plasma clearance was 743 ± 462 ml/minute, and the renal clearance was 18.8 ± 8.49 ml/minute. Within 72 hours, 1.8 ± 0.6% of the administration dose was excreted in urine as mitoxantrone parent compound. From the urinary excretion rate data, glomerular filtration and possible tubular reabsorption were the mechanisms involved in the urinary excretion of mitoxantrone. The values for unbound fraction (%) in plasma at time 0 and 5 minutes were 2.88 ± 0.91% and 3.25 ± 1.19%, with an average of 3.04 ± 1.01%. The degree of protein binding of mitoxantrone was not affected by concentration (P > 0.05) in Chinese patients with NPC. The response rate for mitoxantrone was poor in this study. Clinical studies have demonstrated that mitoxantrone was generally well tolerated. Only very low incidences of nausea, vomiting, and alopecia were observed. The mild and rapidly reversible dose‐limiting hematologic toxic effects have proven leukopenia. Although the toxicities reported here were tolerated for most patients, other combination regimens including mitoxantrone or other administration routes may be considered and need to be evaluated carefully. Cancer 1992; 69:847–853.

AB - The pharmacokinetics and pharmacodynamics of mitoxantrone were studied in 15 patients with advanced nasopharyngeal carcinoma (NPC) after single intravenous rapid infusion (12 to 14 mg/m2). Mitoxantrone plasma concentrations and urinary excretion were measured specifically with the use of a high‐performance liquid chromatographic method with ultraviolet detection at 242 and 658 nm. The pharmacokinetic parameters are described adequately by a three‐compartment model with a terminal half‐life of 71.5 ± 40.1 hours and a volume of distribution of 5037 ± 2377 l0. The total plasma clearance was 743 ± 462 ml/minute, and the renal clearance was 18.8 ± 8.49 ml/minute. Within 72 hours, 1.8 ± 0.6% of the administration dose was excreted in urine as mitoxantrone parent compound. From the urinary excretion rate data, glomerular filtration and possible tubular reabsorption were the mechanisms involved in the urinary excretion of mitoxantrone. The values for unbound fraction (%) in plasma at time 0 and 5 minutes were 2.88 ± 0.91% and 3.25 ± 1.19%, with an average of 3.04 ± 1.01%. The degree of protein binding of mitoxantrone was not affected by concentration (P > 0.05) in Chinese patients with NPC. The response rate for mitoxantrone was poor in this study. Clinical studies have demonstrated that mitoxantrone was generally well tolerated. Only very low incidences of nausea, vomiting, and alopecia were observed. The mild and rapidly reversible dose‐limiting hematologic toxic effects have proven leukopenia. Although the toxicities reported here were tolerated for most patients, other combination regimens including mitoxantrone or other administration routes may be considered and need to be evaluated carefully. Cancer 1992; 69:847–853.

UR - http://www.scopus.com/inward/record.url?scp=0026515566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026515566&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19920215)69:4<847::AID-CNCR2820690402>3.0.CO;2-L

DO - 10.1002/1097-0142(19920215)69:4<847::AID-CNCR2820690402>3.0.CO;2-L

M3 - Article

C2 - 1735075

AN - SCOPUS:0026515566

VL - 69

SP - 847

EP - 853

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -